Analyst Reco. Dr. Reddy's Laboratories Limited NSE India S.E.

Equities

DRREDDY

INE089A01023

Delayed NSE India S.E. Other stock markets 07:36:11 09/05/2024 BST			5-day change	1st Jan Change
5,980 ^INR	-1.26%		-4.89%	+3.14%

05-08	Asian Equities Traded in the US as American Depositary Receipts Trend Slightly Lower in Wednesday Trading	MT
05-08	Indian Equities Settle Flat on Wednesday, Dragged by Banks, FMCG Stocks	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR5,010 From INR5,040, Keeps at Underperform	05-08	MT
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $75, Keeps Overweight Rating	01-29	MT
Indian Equities Bounce Back on Thursday Amid Likelihood of US Rate Cuts in US	01-04	MT
Indian Equities Close Higher on Friday as Major Central Banks Hold Rates Steady	11-03	MT
Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR6,250 From INR6,330, Keeps at Buy	30/10/23	MT
Indian Equities End Lower After US Fed Hints Rates Staying Higher for Longer	21/09/23	MT
Jefferies Adjusts Dr. Reddy Laboratories’ to INR6,300 From INR5,600, Keeps at Buy	27/07/23	MT
Indian Equities Drag as Several Central Banks Hike Interest Rates; Adani Enterprises Slumps 7%	23/06/23	MT
Indian Equites Soar on Friday as Investors Bet on Delay in Further US Rate Hikes	16/06/23	MT
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating	01/06/23	MT
Nomura Adjusts Dr Reddy's Laboratories' Price Target to INR5,161 From INR5,552, Keeps at Buy	30/01/23	MT
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $66 From $69, Reiterates Overweight Rating	25/10/22	MT
Barclays Adjusts Dr. Reddy's Laboratories' Price Target to $69 from $68, Maintains Overweight Rating	12/09/22	MT
Barclays Lowers Dr. Reddy's Laboratories' Price Target to $68 From $70, Maintains Overweight Rating	25/07/22	MT
Nomura Adjusts Dr. Reddy's Laboratories’ Price Target to 5,552 Indian Rupees From 5,856 Indian Rupees, Keeps at Buy	31/01/22	MT
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $78, Maintains Overweight Rating	01/11/21	MT
Nomura Adjusts Dr Reddy's Laboratories' Price Target to 5,856 Indian Rupees From 5,619 Indian Rupees, Keeps at Buy	01/11/21	MT
DR REDDY LABORATORIES : Nomura Adjusts Dr. Reddy's Laboratories' Price Target to 5,619 Indian Rupees From 6,145 Indian Rupees, Keeps at Buy	29/07/21	MT
DR REDDY LABORATORIES' : Price Target From Nomura Raised to INR6,145 From INR5,065, Buy Rating Maintained	18/05/21	MT
DR REDDY LABORATORIES : Nomura Adjusts Dr. Reddy's Laboratories' Price Target to 6,145 Indian Rupees From 5,065 Indian Rupees, Keeps at Buy	18/05/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Dr. Reddy's Laboratories Limited NSE India S.E.

Equities

DRREDDY

INE089A01023

Analyst Reco.

Filters